Prospective Study for Safety and Efficacy of InSpace™ in Rotator Cuff Tear Subjects

Rotator Cuff Tear Clinical Trial

Official title:

One-arm, International, Multi-center With Competitive Recruitment, Prospective Study to Assess the Safety and Efficacy of OrthoSpace's InSpace™ in Rotator Cuff Tear Subjects Scheduled for Surgery of the Rotator Cuff

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00916994
• Other study ID #: BP-04
• Status: Completed
• Phase: N/A
• First received: June 7, 2009
• Last updated: March 10, 2015
• Start date: July 2009
• Est. completion date: June 2014

Study information

• Verified date: June 2013
• Source: OrthoSpace Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Title: One-arm, international, multi-center with competitive recruitment, prospective study to assess the safety and efficacy of OrthoSpace's InSpace™ in rotator cuff tear subjects scheduled for surgery of the rotator cuff - A pivotal study

Device: OrthoSpace's Biodegradable Implanted Balloon (InSpace)

Study population: Rotator Cuff tear subjects scheduled for arthroscopy.

Number of subjects: Up to 70 subject for data analysis.

Number of sites: At least 4 sites in Israel.

Main Inclusion criteria: Informed consent, diagnosed with Rotator Cuff tear.

Main Exclusion criteria: Former surgery on affected shoulder, sever illness, significant shoulder co morbidities.

Follow up period: 12 months. Visits at hospital before discharge at 1-2 days post implantation, 7-10 days post implantation, 3 weeks post implantation, 6 weeks post implantation, 3,6 and 12 months post implantation.

Primary goal: To assess the safety of the SpaceGuard in Rotator Cuff tear subjects.

Secondary goals: To assess the effectiveness of the SpaceGuard in the study population. The effectiveness will be assessed by terms of good positioning of the SpaceGuard and subsequent follow-up non migration, surgeon satisfaction, pain relief and time to pain relief, Range of Motion (ROM) and time to ROM with the SpaceGuard.

Primary end point: Serious Adverse Event rate related to the device and/or system complication.

Secondary end points: Surgeon dissatisfaction following the deployment of SpaceGuard, migration of the balloon shown by ultrasound/ X-ray/MRI at relevant follow-up visits, lost of ROM and pain enhancement.

Description:

The OrthoSpace's InSpace™ biodegradable sub-acromial spacer (balloon) will be inserted at the end of the routine arthroscopy between the humerus head and the acromion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: June 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 or older.

2. Diagnosed with Rotator Cuff tear and are scheduled for surgery.

3. X-Ray of treated shoulder with no unrelated pathology and imaging (ultrasound or MRI) showing Rotator Cuff tear.

4. Persistent pain and functional disability for at least 4 months.

5. Documented failure of conservative treatment.

6. Blood work up to two weeks before implantation as follow:

• Normal CBC

• Normal electrolytes (potassium, chloride, phosphorous, sodium)

• Absolute neutrophil count (ANC) = 1,800 cells/mm3

• Platelets = 100,000 cells/mm3

• Hemoglobin = 10.0 g/dl

• Adequate renal function, with serum creatinine = 2.0 mg/dl

• Adequate liver function, with serum bilirubin < 2.0 mg/dl

• Adequate liver function with SGOT/SGPT < 2.5 x the upper normal limit

• Normal values of the PT, PTT and INR tests

7. Negative for HIV and Hepatitis B or C

8. Mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements

9. For Woman of Child Bearing Potential (WOCBP), negative pregnancy test and willingness to use birth control during the study.

10. Singed Informed Consent Form.

Exclusion Criteria:

1. Evidence of significant osteoarthritis or cartilage damage in the shoulder.

2. Evidence of glenohumeral instability.

3. Previous surgeries of the shoulder .

4. Evidence of major joint trauma, infection, or necrosis in the shoulder.

5. Patients unable to provide informed consent due to language barrier or mental status.

6. Patients with a major medical condition that would affect quality of life and influence the results of the study (Including, but not limited to HIV, hepatitis, active malignancy in the past 5 years, transmural MI, CVA and other impaired neurological status, CHF or unstable angina in the past 6 months).

7. Patients unwilling to be followed for the duration of the study.

8. Acute infection requiring intravenous antibiotics at the time of screening.

9. Other shoulder pain of unknown etiology.

10. Paget's disease, osteomalacia or any other metabolic bone disease.

11. Severe diabetes mellitus requiring daily insulin management.

12. Bleeding disorders.

13. Known cognitive disorder.

14. Concurrent participation in any other clinical study.

15. Physician objection.

16. Subjects with sign of cervical root irritation.

17. Chronic lung disease

18. Trauma subjects

19. For WOCBP, a positive pregnancy test.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Rotator Cuff Tear

Intervention

Device:
• SpaceGuard Balloon
Positioning of the balloon into the subacromial space between the humerus head and the acromion

Locations

Country	Name	City	State
Israel	Wolfson Medical Center	Holon

Sponsors (1)

Lead Sponsor	Collaborator
OrthoSpace Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The study's primary goal is to assess the safety of the SpaceGuard and implantation procedure, in the study population. Safety of the SpaceGuard will be assessed by reporting system related adverse events.		12-36 months follow-up	Yes